These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32410559)

  • 21. Liver volume as a determinant of drug clearance in children and adolescents.
    Murry DJ; Crom WR; Reddick WE; Bhargava R; Evans WE
    Drug Metab Dispos; 1995 Oct; 23(10):1110-6. PubMed ID: 8654200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin.
    Boxenbaum H
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):165-76. PubMed ID: 6107379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipyrine disposition and liver size in the elderly.
    Swift CG; Homeida M; Halliwell M; Roberts CJ
    Eur J Clin Pharmacol; 1978 Nov; 14(2):149-52. PubMed ID: 720377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects.
    Andersen V; Sonne J; Larsen S
    Scand J Gastroenterol; 1999 Aug; 34(8):813-7. PubMed ID: 10499483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of obesity on the pharmacokinetics of drugs in humans.
    Hanley MJ; Abernethy DR; Greenblatt DJ
    Clin Pharmacokinet; 2010; 49(2):71-87. PubMed ID: 20067334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of human pharmacokinetics for low-clearance compounds using pharmacokinetic data from chimeric mice with humanized livers.
    Yoshida K; Doi Y; Iwazaki N; Yasuhara H; Ikenaga Y; Shimizu H; Nakada T; Watanabe T; Tateno C; Sanoh S; Kotake Y
    Clin Transl Sci; 2022 Jan; 15(1):79-91. PubMed ID: 34080287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the Pharmacokinetic Mysteries of the Liver: Application of Series Compartment Models of Hepatic Elimination.
    Li X; Jusko WJ
    Drug Metab Dispos; 2023 May; 51(5):618-628. PubMed ID: 36732075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disposition of antipyrine and phenytoin correlated with age and liver volume in man.
    Bach B; Hansen JM; Kampmann JP; Rasmussen SN; Skovsted L
    Clin Pharmacokinet; 1981; 6(5):389-96. PubMed ID: 7333060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigating the Theoretical Basis for In Vitro-In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways.
    Benet LZ; Sodhi JK
    AAPS J; 2020 Sep; 22(5):120. PubMed ID: 32914238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between antipyrine elimination rate constant, clearance and volume of distribution in the rat.
    Svensson CK
    J Pharm Pharmacol; 1987 Oct; 39(10):838-9. PubMed ID: 2891823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can In Vitro-In Vivo Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions.
    Benet LZ; Sodhi JK
    Clin Pharmacol Ther; 2022 May; 111(5):1022-1035. PubMed ID: 34731496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man.
    Sonne J; Dragsted J; Loft S; Døssing M; Andreasen F
    Eur J Clin Pharmacol; 1989; 36(4):407-9. PubMed ID: 2737234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative assessment of In Vitro-In Vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs.
    Poulin P; Hop CE; Ho Q; Halladay JS; Haddad S; Kenny JR
    J Pharm Sci; 2012 Nov; 101(11):4308-26. PubMed ID: 22890957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipyrine clearance and metabolite formation: the influence of liver volume and smoking.
    Spoelstra P; Teunissen MW; Janssens AR; Weeda B; van Duijn W; Koch CW; Breimer DD
    Eur J Clin Invest; 1986 Aug; 16(4):321-7. PubMed ID: 3093244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement.
    Sotaniemi EA; Pelkonen O; Arranto AJ; Tapanainen P; Rautio A; Pasanen M
    Pharmacol Toxicol; 2002 Mar; 90(3):155-60. PubMed ID: 12071338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition.
    Buters JT; Zysset T; Reichen J
    Biochem Pharmacol; 1993 Sep; 46(6):983-91. PubMed ID: 8216358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced hepatic drug clearance in patients with cystic fibrosis.
    Kearns GL; Mallory GB; Crom WR; Evans WE
    J Pediatr; 1990 Dec; 117(6):972-9. PubMed ID: 2246703
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Morita K; Kato M; Kudo T; Ito K
    Xenobiotica; 2020 Sep; 50(9):1064-1075. PubMed ID: 32125203
    [No Abstract]   [Full Text] [Related]  

  • 40. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
    Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
    Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.